IC
NBIX icon

Ikarian Capital’s Neurocrine Biosciences NBIX Stock Holding History

Ikarian Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,000
Closed -$7.23M – 194
2025
Q4 		$7.23M Buy
+51,000
New +$7.39M 0.56% 52
2024
Q3 		– Sell
-1,000
Closed -$13.8M – 164
2024
Q2 		$13.8M Buy
+1,000
New +$137K 2.4% 13
2022
Q2 		– Sell
-429,600
Closed -$40.3M – 178
2022
Q1 		$40.3M Buy
+429,600
New +$36.4M 5.3% 2
2021
Q1 		– Sell
-23,700
Closed -$2.27M – 321
2020
Q4 		$2.27M Buy
+23,700
New +$2.29M 0.1% 146
2020
Q2 		– Sell
-100,000
Closed -$8.65M – 196
2020
Q1 		$8.65M Buy
100,000
+92,800
+1,289% +$9.08M 0.65% 40
2019
Q4 		$774K Buy
+7,200
New +$754K 0.13% 84

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital's NBIX Position: Q1 2026 in Review

Ikarian Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 54,062 shares — an estimated $7.67M sold.

Ikarian Capital first reported a position in NBIX in Q2 2022 and held it in 3 quarters. The position peaked at $7.67M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Ikarian Capital reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 54,062 Neurocrine Biosciences shares in Q1 2026, an estimated $7.67M.
  • Ikarian Capital first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 3 quarters.
  • Ikarian Capital's Neurocrine Biosciences position peaked at $7.67M in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.